Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.52 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 5/20 | 0.49 |
| ▸ | CA1 | P00915 | 4/20 | 0.49 |
| ▸ | CA2 | P00918 | 4/20 | 0.49 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 7/20 | 0.42 |
| ▸ | DRD3 | P35462 | 3/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | HTR1D | P28221 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4736598 | 0.91 | EPHX2 (0.44) | MTNR1AMTNR1BCA1CA2EPHX2 | |
| SCHEMBL7035289 | 0.90 | MTNR1A (0.53) | MTNR1AMTNR1BACHECA1CA2 | |
| SCHEMBL5681677 | 0.90 | MTNR1A (0.53) | MTNR1AMTNR1BACHECA1CA2 | |
| SCHEMBL9443694 | 0.86 | ADRB3 (0.51) | MTNR1AMTNR1BACHECA1CA2 | |
| SCHEMBL9443701 | 0.86 | ADRB3 (0.51) | MTNR1AMTNR1BACHECA1CA2 | |
| SCHEMBL9443665 | 0.86 | ADRB3 (0.51) | MTNR1AMTNR1BACHECA1CA2 | |
| SCHEMBL5681735 | 0.85 | ACHE (0.48) | MTNR1AMTNR1BACHECA1CA2 | |
| SCHEMBL5679385 | 0.84 | RAB9A (0.48) | MTNR1AMTNR1BACHECA1CA2 | |
| SCHEMBL5677381 | 0.83 | HDAC8 (0.50) | MTNR1AMTNR1BACHECA1CA2 | |
| SCHEMBL5722257 | 0.83 | MTNR1A (0.50) | MTNR1AMTNR1BACHECA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030160-B2 | Propanolaminotetralines, preparation thereof and compositions containing same | SANOFI-AVENTIS (FR) | 2006-04-18 | — | — | US | disclosed |
| US-20040034070-A1 | Propanolaminotetralines, preparation thereof and compositions containing same | SANOFI-AVENTIS (FR) | 2004-02-19 | — | — | US | disclosed |
| EP-1292572-B1 | PROPANOLAMINOTETRALINES, PREPARATION THEREOF AND COMPOSITIONS CONTAINING SAME | SANOFI SYNTHELABO (FR) | 2004-02-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034070-A1 | Propanolaminotetralines, preparation thereof and compositions containing same | ADRB3, ADRB1, ADRB2 | MTNR1A 627/4885MTNR1B 286/4885ACHE 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.